{
    "nct_id": "NCT03650114",
    "official_title": "An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis",
    "inclusion_criteria": "1. Must have completed a selected Novartis MS study which dosed ofatumumab 20 mg sc every 4 weeks\n2. Written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Emergence of any clinically significant condition/disease during the previous ofatumumab study in which study participation might result in safety risk for the subject\n* Subjects with active systemic bacterial, viral or fingal infections, or chronic infection (e.g. AIDS)\n* Subjects taking medications prohibited by the protocol\n* Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may apply\n\nVaccination sub-study:\n\nInclusion criteria\n\n1. Informed consent\n2. Actively enrolled in the COMB157G2399 Study\n3. 12 weeks of continuous treatment within the COMB157G2399 Study\n4. prior vaccination history as per protocol-defined\n\nExclusion criteria\n\n* known hypersensitivity or history of systemic allergic, neurologic or other reactions to vaccines\n* allergies to egg or shellfish\n* any safety findings including low IgG/IgM requiring ofatumumab interruption within 12 weeks prior to vaccination sub-study start\n* any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 2 weeks of the first vaccination sub-study visit\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": ""
}